Eastman Ronald W

CIK 00015975856 companiesPALO ALTO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001597585

Recent Transactions

35 trades

Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−20,000→ 0 total
Disposition from Tender
Corium International, Inc.
Common Stock
2018-11-27$12.50/sh−9,353,304→ 0 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−15,000→ 0 total
Disposition to Issuer
Corium International, Inc.
Director Stock Option (Right to Buy)
2018-11-27$12.50/sh−15,000→ 0 total
Award
Corium International, Inc.
Director Stock Option (Right to Buy)
2017-12-01+15,000→ 15,000 total
Award
Revance Therapeutics, Inc.
Common Stock
2017-05-11+3,000→ 3,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2017-05-11+6,000→ 6,000 total
Award
Corium International, Inc.
Director Stock Option (Right to Buy)
2016-12-22+15,000→ 15,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2016-05-05+8,000→ 8,000 total
Award
Corium International, Inc.
Director Stock Option (right to buy)
2015-12-18+20,000→ 20,000 total
Award
Revance Therapeutics, Inc.
Stock Option (Right to Buy)
2015-05-07+8,000→ 8,000 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+2,781,396→ 2,781,396 total
Exercise of In-Money
Revance Therapeutics, Inc.
Common Stock
2014-02-11+369,124→ 3,747,332 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+200,538→ 200,538 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+43,029→ 243,567 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+87,190→ 87,190 total
Exercise of In-Money
Revance Therapeutics, Inc.
Common Stock
2014-02-11+11,560→ 117,458 total
Conversion
Revance Therapeutics, Inc.
Series E-3 Convertible Preferred Stock
2014-02-11−575,384→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-4 Convertible Preferred Stock
2014-02-11−1,801,888→ 0 total
Exercise of In-Money
Revance Therapeutics, Inc.
Warrant to Purchase Common Stock
2014-02-11−369,124→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-4 Convertible Preferred Stock
2014-02-11−129,916→ 0 total
Conversion
Revance Therapeutics, Inc.
Convertible Promissory Notes
2014-02-11−43,029→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-3 Convertible Preferred Stock
2014-02-11−18,037→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-5 Convertible Preferred Stock
2014-02-11−12,668→ 0 total
Conversion
Revance Therapeutics, Inc.
Convertible Promissory Notes
2014-02-11−18,708→ 0 total
Exercise of In-Money
Revance Therapeutics, Inc.
Common Stock
2014-02-11+26,605→ 270,172 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+18,708→ 105,898 total
Conversion
Revance Therapeutics, Inc.
Convertible Promissory Notes
2014-02-11−596,812→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-3 Convertible Preferred Stock
2014-02-11−41,485→ 0 total
Conversion
Revance Therapeutics, Inc.
Common Stock
2014-02-11+596,812→ 3,378,208 total
Conversion
Revance Therapeutics, Inc.
Series E-5 Convertible Preferred Stock
2014-02-11−404,124→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-5 Convertible Preferred Stock
2014-02-11−29,137→ 0 total
Exercise of In-Money
Revance Therapeutics, Inc.
Warrant to Purchase Common Stock
2014-02-11−26,605→ 0 total
Conversion
Revance Therapeutics, Inc.
Series E-4 Convertible Preferred Stock
2014-02-11−56,485→ 0 total
Exercise of In-Money
Revance Therapeutics, Inc.
Warrant to Purchase Common Stock
2014-02-11−11,560→ 0 total

Companies

Recent Filings

Address

C/O ESSEX WOODLANDS HEALTH VENTURES 335 BRYANT STREET, THIRD FLOOR

PALO ALTO, CA, 94301

View on SEC.gov